March 12th webinar: Venture philanthropy deal-making
The Cystic Fibrosis Foundation’s recent return on investment in Kalydeco has placed a magnifying glass on the venture philanthropy model and its business-minded approach to funding for-profit biotech and pharma companies. Driven by the urgency to find treatments and cures for their own diseases, these patient-powered foundations are often the players with the greatest incentive to make strategic, early-stage investments that accelerate solutions, and an increasing number are applying the principles of venture philanthropy to help push promising science through the pipeline. As the focus on venture philanthropy increases, new questions are arising about the structure and impact of these deals. Tune in and hear answers from legal experts, foundations, and companies about what the details of these deals look like, what results are being achieved, and what interested foundations might need to know before going down this path.
- Louis DeGennaro, President and CEO, Leukemia & Lymphoma Society
- Ken Schaner, Partner, Schaner & Lubitz, PLLC
- Industry speaker to be announced
- Margaret Anderson, Executive Director, FasterCures, Moderator